|
1
|
Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF and Sung JJ: Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries. Eur Urol. 7:862–874. 2016. View Article : Google Scholar
|
|
2
|
Crawford ED, Higano CS, Shore ND, Hussain M and Petrylak DP: Treating patients with metastatic castration resistant prostate cancer: A comprehensive review of available therapies. J Urol. 194:1537–1547. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Dodewaard-de Jong JM, Verheul HMW, Bloemendal HJ, de Klerk JMH, Carducci MA and van den Eertwegh AJM: New Treatment options for patients with metastatic prostate cancer: What is the optimal sequence? Clin Genitourin Cancer. 13:271–279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jackson SP and Bartek J: The DNA-damage response in human biology and disease. Nature. 461:1071–1078. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hah SS, Mundt JM, Kim HM, Sumbad RA, Turteltaub KW and Henderson PT: Measurement of 7,8-dihydro-8-oxo-2′-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc Natl Acad Sci USA. 104:11203–11208. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Du Y, Le W, Wang K, Kieffer N and Zhang J: Redox control of the survival of healthy and diseased cells. Antioxid Redox Signal. 15:2867–2908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakabeppu Y: Cellular levels of 8-oxoguanine in either DNA or the nucleotide pool play pivotal roles in carcinogenesis and survival of cancer cells. Int J Mol Sci. 15:12543–12557. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, Schultz N, Lundback T, Einarsdottir BO, et al: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 508:215–221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kennedy CH, Pass HI and Mitchell JB: Overexpression of human mutT homologue (hMTH1) protein as a marker of persistent oxidative stress in primary non-small cell lung tumors. Free Radic Biol Med. 34:1447–1457. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iida T, Furuta A, Kawashima M, Nishida J, Nakabeppu Y and Iwaki T: Accumulation of 8-oxo-2′-deoxyguanosine and increased expression of hMTH1 protein in brain tumors. Neuro Oncol. 3:73–81. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tu Y, Wang Z, Wang X, Yang H, Zhang P, Johnson M, Liu N, Liu H, Jin W, Zhang Y, et al: Birth of MTH1 as a therapeutic target for glioblastoma: MTH1 is indispensable for glioma tumorigenesis. Am J Transl Res. 8:2803–2811. 2016.PubMed/NCBI
|
|
12
|
Okamoto K, Toyokuni S, Kim WJ, Ogawa O, Kakehi Y, Arao S, Hiai H and Yoshida O: Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: Evidence of persistent oxidative stress in cancer. Int J Cancer. 65:437–441. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Song W, Zhou Y, Mao F, Lin Y, Guan J and Sun Q: Expression and function of MutT homolog 1 in distinct sub-types of breast cancer. Oncol Lett. 13:2161–2168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koketsu S, Watanabe T and Nagawa H: Expression of DNA repair protein: MYH, NTH1, and MTH1 in colorectal cancer. Hepatogastroenterology. 51:638–642. 2004.PubMed/NCBI
|
|
15
|
Akiyama S, Saeki H, Nakashima Y, Iimori M, Kitao H, Oki E. Oda Y, Nakabeppu Y, Kakeji Y and Maehara Y: Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma. Cancer Med. 6:258–266. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rai P, Young JJ, Burton DG, Giribaldi MG, Onder TT and Weinberg RA: Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence. Oncogene. 30:1489–1496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Gokturk C, Sanjiv K, Strömberg K, et al: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 508:222–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, Gokturk C, Jafari R, Maddalo G, Seashore-Ludlow B, et al: Validation and development of MTH1 inhibitors for treatment of cancer. Ann Oncol. 27:2275–2283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kettle JG, Alwan H, Bista M, Breed J, Davies NL, Eckersley K, Fillery S, Foote KM, Goodwin L, Jones DR, et al: Potent and selective inhibitors of MTH1 probe its role in cancer cell survival. J Med Chem. 59:2346–2361. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Petrocchi A, Leo E, Reyna NJ, Hamilton MM, Shi X, Parker CA, Mseeh F, Bardenhagen JP, Leonard P, Cross JB, et al: Identification of potent and selective MTH1 inhibitors. Bioorg Med Chem Lett. 26:1503–1507. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kawamura T, Kawatani M, Muroi M, Kondoh Y, Futamura Y, Aono H, Tanaka M, Honda K and Osada H: Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival. Sci Rep. 6:265212016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scobie M, Helleday T, Koolmeister T, Jacques S, Desroses M and Jacques-cordonnier M: Pyrimidine-2,4-diamine derivatives for treatment of cancer. WO2014084778.
|
|
23
|
Pudelko L, Rouhi P, Sanjiv K, Gad H, Kalderén C, Höglund A, Squatrito M, Schuhmacher AJ, Edwards S, Hägerstrand D, et al: Glioblastoma and glioblastoma stem cells are dependent on functional MTH1. Oncotarget. 8:84671–84684. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hua X, Sanjiv K, Gad H, Pham T, Gokturk C, Rasti A, Zhao Z, He K, Feng M, Zang Y, et al: Karonudib is a promising anticancer therapy in hepatocellular carcinoma. Ther Adv Med Oncol. 11:17588359198669602019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Das I, Gad H, Brautigam L, Pudelko L, Tuminen R, Helleday T, Hansson J, Brage S and Berglund U: 1180 Effects of MTH1 inhibitor TH1579 on cutaneous melanoma. J Invest Dermat. 138:S2002018. View Article : Google Scholar
|
|
26
|
Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Olofsson Bagge R, Carstam L, Carstam L, et al: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death Dis. 9:8102018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou W, Ma L, Yang J, Qiao H, Li L, Guo Q, Ma J, Zhao L, Wang J, Jiang G, et al: Potent and specific MTH1 inhibitors targeting gastric cancer. Cell Death Dis. 10:4342019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JW, Lee S, Ho JN, Youn JI, Byun SS and Lee E: Antitumor effects of MutT homolog 1 inhibitors in human bladder cancer cells. Biosci Biotechnol Biochem. 83:2265–2271. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carroll AG, Voeller HJ, Sugars L and Gelmann EP: p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 23:123–134. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mamidi TKK, Wu J and Hicks C: Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer. BMC Cancer. 19:2292019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, et al: Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 8:3742017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Popovics P, Schally AV, Szalontay L, Block NL and Rick FG: Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget. 5:4567–4578. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lorente D, Mateo J, Perez-Lopez R, de Bono JS and Attard G: Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 16:e279–292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Knudsen KE: The AR-DNA repair axis: Insights into prostate cancer aggressiveness. Can J Urol. 26 (5 Suppl 2):S22–S23. 2019.
|
|
35
|
Nakabeppu Y, Ohta E and Abolhassani N: MTH1 as a nucleotide pool sanitizing enzyme: Friend or foe? Free Radic Biol Med. 107:151–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
